Intellia Therapeutics, Inc. (NASDAQ:NTLA) Faces Clinical Trial Challenges

Font: Financial Modeling Prep  • Oct 27, 2025

• H.C. Wainwright upgraded Intellia Therapeutics, Inc. (NASDAQ:NTLA) to a "Buy" rating but lowered its price target due to recent clinical trial issues.
• A safety event in the MAGNITUDE clinical trials for transthyretin amyloidosis led to a protocol pause, highlighting the risks in gene-editing therapies.
• The stock has experienced significant volatility, with a current price of $14.42, reflecting a decrease of 43.67% from its previous value.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage biotechnology company focused on developing gene-editing therapies. The company is known for its pioneering work in CRISPR/Cas9 technology, which aims to treat genetic diseases. Intellia's competitors include other biotech firms like CRISPR Therapeutics and Editas Medicine, which are also exploring gene-editing solutions.

On October 27, 2025, H.C. Wainwright upgraded Intellia Therapeutics to a "Buy" rating, with the stock priced at approximately $14.68. Despite this positive outlook, the firm lowered its price target from $30 to $25. This adjustment reflects the challenges Intellia faces, particularly with its recent clinical trial issues.

Intellia recently announced a safety event in its MAGNITUDE clinical trials, leading to a protocol pause. This decision follows a serious liver issue in a patient, highlighting the risks in gene-editing therapies. The pause affects trials for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN).

The stock for NTLA is currently priced at $14.42, showing a significant decrease of 43.67% from its previous value. The stock has fluctuated between $13.21 and $16.76 during the day. Over the past year, it reached a high of $28.25 and a low of $5.90, indicating volatility.

Intellia's market capitalization stands at approximately $1.55 billion, with a trading volume of 37.32 million shares on the NASDAQ exchange. The company's recent challenges may impact investor sentiment and its future progress in the competitive gene-editing field.